Dan Vahdat’s Post

📢 Announcement! OMF's First Clinical Trial! Today marks the first day of our Triple Giving November campaign – where your donations to OMF are TRIPLED until November 30, 2023! To kick off our most exciting time of the year, we have some big news. 🔬 Introducing The LIFT Trial! Our first-ever clinical trial is here: The Life Improvement Trial (LIFT) is a major step towards better understanding and treating ME/CFS more effectively. 🧪 What's The LIFT? Conducted under the direction of David Systrom, MD, Director of our Harvard Collaboration and Jonas Bergquist, MD, PhD, OMF's Chief Medical Officer and Director of the Uppsala University Collaboration, The LIFT is a randomized, double-blind placebo trial that will investigate two particular drugs: Pyridostigmine (commonly known as Mestinon) and low-dose naltrexone (LDN) separately and together as a combination. For more information, read the full announcement here 👉 https://lnkd.in/eMxwG5YE. 🗓️ When does the trial start, and how are we recruiting? This trial is planned to start before the end of the year. David Systrom and Jonas Bergquist are the lead investigators and will be recruiting from their patients in the Boston area as well as participants who have signed up through OMF's StudyME as needed. 🤝 Join Our Mission The success of The LIFT trial and our future clinical trials significantly depend on the collective support from our community. Your donation, especially during our Triple Giving November campaign, can make a monumental difference. Remember, every donation you make in November will be tripled, amplifying the impact of your support. 👉 Donate now and TRIPLE your impact: https://ow.ly/4s5O50Q2NyN.

Budget for Cancer Screening <<<<<< Budget for Cancer Treatment The national budget for cancer treatment is not even close to cancer screening and prevention There is a significant funding gap between cancer treatment and cancer prevention/screening. While billions are allocated annually to develop and administer new cancer treatments, preventive measures and early detection efforts receive comparatively less support. 🔬 Cancer Treatment: The National Cancer Institute (NCI) alone dedicates a substantial portion of its $6.9 billion budget to cancer treatment research. Pharmaceutical companies also invest heavily in developing new cancer therapies, driven by potential high returns on investment. 🔍 Cancer Prevention and Screening: Initiatives like the HRSA’s Accelerating Cancer Screening (AxCS) Initiative invest millions to improve screening access (not Billions), but this pales in comparison to treatment funding. It is frustrating to see how much money we spend on drugs, but much less on developing new screening tests. Resources: https://loom.ly/-R4VRbY https://loom.ly/HP0XWUQ https://loom.ly/RoK9Zgk #CancerResearch #HealthcareFunding #CancerPrevention #EarlyDetection #PublicHealth #NCI #HRSA #HealthDisparities

Clinical trials are the engine that moves science forward to diagnose faster and treat better. Clinical trials are complex and require large teams of people to ensure they are meticulously designed, safely conducted, and effectively managed. For childhood cancer, clinical trials have changed the way the disease is treated - with combination therapies, and novel treatments such as immunotherapy. We are grateful to those who have dedicated their lives to make sure science happens safely and effectively. Kindred Foundation, in partnership with Phoebe Rose Rocks, created the U-Link Patient and Family Fund to provide financial support for families across Canada who must travel to access clinical trials for children, adolescents, and young adults with cancer. This fund helps families directly with the costs of travel to ensure that their child can access treatment, no matter where they live in Canada. https://lnkd.in/drpuiwM4 Health professionals, patients, and families can find information on childhood cancer clinical trials and various resources in Canada by visiting https://u-link.care/ #ClinicalTrialsDay #CTD2024

🌟 Dive into the highlights of our recent #ThinkTankMeeting in São Paulo, Brazil, where international mentors and dedicated Brazilian oncologists joined forces to redefine the landscape of clinical trials. Special thanks to all attendees, mentors and AstraZeneca. Read more: https://lnkd.in/dya4pwTZ  #oncologyresearch #clinicaltrials

#AACR24, I will be there! Join me at booth #4117 to learn how ERBC (European Research Biology Center) Group facilitates the evaluation of cancer drug candidates from preclinical proof of concept to market success. Let's network and explore opportunities together. See you there! 🚀 #lifescience #oncology #CRO #partnering #drugdevelopment 

Last chance to support our fundraising efforts for Cancer Research UK! Cancer affects so many of us, including myself, and every contribution, no matter how small, makes a difference. Plus, Microsoft is generously matching donations. Join me in making a difference by donating here: https://lnkd.in/ehTYzcPY. Remember to list my name in the donations for tracking purposes! Did you know that in the UK alone, there were over 375,000 new cases of cancer between 2016 and 2018? Shockingly, one in two people in the UK will be diagnosed with cancer at some point in their lives. Supporting Cancer Research UK is crucial, as 38% of cancers are preventable. When you support Cancer Research UK, you fund vital research that leads to scientific breakthroughs and personal triumphs. Together, we can make a real difference in the fight against cancer. Additionally, consider joining the International Association of Microsoft Channel Partners (IAMCP) to connect with like-minded professionals and find the perfect partner match. With over 2,000 members and events across 40 countries, IAMCP offers valuable opportunities for growth and collaboration. Visit their website to learn more and join today! #Charity #FundRaising #CancerUK #Cancer #Football #Microsoft

When you take a moment to look around, you will realize that everyone’s lives have in one way, or another been touched by cancer. Just one of many important reasons why we at GILEAD are committed to bringing more possibilities to people with cancer. We believe that making progress in cancer research requires a strategy built on the power of partnerships and groundbreaking technologies. This is why we are extremely pleased that the “Expanding Horizons in Oncology” Award is going into its second round. Partnering up with the @SAKK Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, the Swiss Group for Clinical Cancer Research, GILEAD will provide funding for ongoing education in the field of oncology, pledging a total of CHF 40’000. You can find all details on https://lnkd.in/evM9Ymnk and apply until September 30, 2023. We are looking forward to learning more about your ideas and projects. Together, we can make progress for people with cancer! #gilead #creatingpossible #gileadswitzerland #sakk #cancer #oncology #healthcare #research

I cannot even put into words, the power, courage, and perseverance that Peter Mang and Katie Mang continue to model in a world where #cancer hits close to home. If you wanna learn more about Pete and Katie‘s journey, or the impacts of glioblastoma and how you can help, follow Go With The Good Foundation connect with Katie Mang and Julie Wilson. #glioblastoma #kindnessmatters #helpingothers #womenwholead

4% to 11%!! I’m happy to share demonstrable outcomes in increasing cancer patient access to clinical trials from our collaboration with Altru Health System In the rural communities stretching across North Dakota and Minnesota, accessing oncology #clinicaltrials can be challenging. Paradigm partnered with Altru Health System to increase clinical trial participation across their 225k patients in rural North Dakota and Minnesota. We’re happy to share that this collaboration increased patient participation in clinical trials from 4% to 11% of the total cancer population, well above the national average for oncology programs, across Altru’s massive rural service area in North Dakota in Minnesota. This means that more patients received access to interventional clinical trials as part of their routine care. This was accomplished by increasing pre-screening and simplifying the enrollment process, while simultaneously reducing Altru staff burden through effective use of the Paradigm platform and clinical services. A step-change in clinical trial participation acts as both an equalizer between rural and urban care, and an accelerating force for the broader research and development ecosystem, ultimately increasing the potential for more patients to benefit from new trials today and accelerating bringing new treatments to market. We’re grateful for Altru’s partnership in this effort and proud to serve their patient community. If you’d like to learn more about working with Paradigm please reach out! https://lnkd.in/gwBg2dCc

Clinical trials are not only life-changing for patients; they bring us closer to finding new cures. As cancer rates rise, these trials are more important than ever, yet 80% of clinical trials are delayed or closed due to recruitment challenges. For many patients, expenses like travel and lodging costs deter them from participating. Our Clinical Trial Access Fund, Powered by the HealthWell Foundation, allows us to remove these barriers, improve survival rates, and create a world where everyone can be a part of the future of science. #ClinicalTrialsDay #CTD2024